Cargando…

Real‐life experience with non‐vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation

BACKGROUND: Nonvitamin K antagonist oral anticoagulants (NOACs) are increasingly used in patients with atrial fibrillation (AF) undergoing elective cardioversion (ECV). The aim was to investigate the use of NOACs and warfarin in ECV in a real‐life setting and to assess how the chosen regimen affecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Itäinen‐Strömberg, Saga, Hekkala, Anna‐Mari, Aro, Aapo L., Vasankari, Tuija, Airaksinen, Kari Eino Juhani, Lehto, Mika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507546/ https://www.ncbi.nlm.nih.gov/pubmed/32348026 http://dx.doi.org/10.1111/anec.12766

Ejemplares similares

Prediction of ineffective elective cardioversion of atrial fibrillation: a retrospective multi-center patient cohort study
por: Hellman, Tapio, et al.
Publicado: (2017)

Comprehensive nationwide incidence and prevalence trends of atrial fibrillation in Finland
por: Lehto, Mika, et al.
Publicado: (2022)

Socioeconomic disparities in use of rhythm control therapies in patients with incident atrial fibrillation: A Finnish nationwide cohort study
por: Teppo, Konsta, et al.
Publicado: (2022)

Rural–Urban differences in Use of Rhythm Control Therapies in Patients with Incident Atrial Fibrillation: A Finnish Nationwide Cohort Study
por: Teppo, Konsta, et al.
Publicado: (2022)

Advanced interatrial block predicts ineffective cardioversion of atrial fibrillation: a FinCV2 cohort study
por: Relander, Arto, et al.
Publicado: (2021)

Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
por: Papp, Judit, et al.
Publicado: (2017)

Frequency of cardioversions as an additional risk factor for stroke in atrial fibrillation – the FinCV-4 study
por: Jaakkola, Samuli, et al.
Publicado: (2022)

How to Optimize Cardioversion of Atrial Fibrillation
por: Airaksinen, K. E. Juhani
Publicado: (2022)

Corrigendum to: Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
Publicado: (2018)

The nationwide Finnish anticoagulation in atrial fibrillation (FinACAF): study rationale, design, and patient characteristics
por: Lehto, Mika, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience
por: Shibata, Naoki, et al.
Publicado: (2017)

The effect of mental health conditions on the use of oral anticoagulation therapy in patients with atrial fibrillation: the FinACAF study
por: Jaakkola, Jussi, et al.
Publicado: (2021)

Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
por: Jaakkola, Samuli, et al.
Publicado: (2017)

Mental health conditions and use of rhythm control therapies in patients with atrial fibrillation: a nationwide cohort study
por: Teppo, Konsta, et al.
Publicado: (2022)

Comparing the delay with different anticoagulants before elective electrical cardioversion for atrial fibrillation/flutter
por: Wall, Christopher, et al.
Publicado: (2019)

Elective cardioversion of atrial fibrillation is safe without transesophageal echocardiography in patients treated with non-vitamin K antagonist oral anticoagulants: Multicenter experience
por: Gorczyca, Iwona, et al.
Publicado: (2023)

Lower dose direct oral anticoagulation or warfarin in atrial fibrillation. Which one is the best when time on therapeutic range information is available?
por: Luojus, A, et al.
Publicado: (2023)

Reliability of pulse palpation in the detection of atrial fibrillation in an elderly population
por: Jaakkola, Jussi, et al.
Publicado: (2017)

The impact of mental health conditions on oral anticoagulation therapy and outcomes in patients with atrial fibrillation: A systematic review and meta-analysis
por: Teppo, Konsta, et al.
Publicado: (2021)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Self-detection of atrial fibrillation in an aged population: three-year follow-up of the LietoAF intervention study
por: Jaakkola, Jussi, et al.
Publicado: (2017)

Income and outcomes of patients with incident atrial fibrillation
por: Biancari, Fausto, et al.
Publicado: (2022)

Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study
por: Bah, Aissa, et al.
Publicado: (2021)

How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study
por: Lehto, M, et al.
Publicado: (2023)

Red blood cell transfusion induces abnormal HIF-1α response to cytokine storm after adult cardiac surgery
por: Viikinkoski, Emma, et al.
Publicado: (2021)

SAFETY AND EFFICACY OF SAME-DAY ELECTIVE CORONARY ANGIOGRAPHY AND SYNCHRONIZED CARDIOVERSION IN PATIENTS WITH ATRIAL FIBRILLATION WITH UNINTERRUPTED ANTICOAGULATION
por: Gallen, Rory, et al.
Publicado: (2021)

Cardioversion of Atrial Arrhythmias: Audit of Anticoagulation Management
por: Mayet, Jamil, et al.
Publicado: (1997)

Non-vitamin K antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: A trans-esophageal echocardiography study
por: Kim, Yun Gi, et al.
Publicado: (2018)

Trends in treatment and outcomes of atrial fibrillation during 2007–17 in Finland
por: Teppo, Konsta, et al.
Publicado: (2022)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion
por: Warden, Bruce A., et al.
Publicado: (2018)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland
por: Vuorinen, Anna-Leena, et al.
Publicado: (2021)

Assessing an Electronic Health Record research platform for identification of clinical trial participants
por: Laaksonen, Niina, et al.
Publicado: (2020)

Are coronary event rates declining slower in women than in men – evidence from two population-based myocardial infarction registers in Finland?
por: Lehto, Hanna-Riikka, et al.
Publicado: (2007)

Sternal fracture after elective electrical cardioversion of atrial fibrillation
por: Vollmann, Dirk, et al.
Publicado: (2010)

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
por: Jacobs, Maartje S., et al.
Publicado: (2017)

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2015)

Aortic Stenosis and Outcomes in Patients With Atrial Fibrillation: A Nationwide Cohort Study
por: Teppo, Konsta, et al.
Publicado: (2023)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sjjje7ilj4pmsmi5guti9vr3pd